GlassScriptPhysician profile
Robert J Lazar
NPI 1831150770
$35,408.27
in general payments reported to CMS, 2019-2025
37 companies · $3,187 in 2025
The $3,187 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,574 · 2021: $2,006 · 2022: $2,501 · 2023: $3,907 · 2024: $6,987 · 2025: $3,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,100 · Consulting Fee: $4,731 · Travel and Lodging: $215 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,099.62 |
| Consulting Fee | $4,731.26 |
| Travel and Lodging | $215.46 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $14,599.29 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pharming Healthcare, INC. | $5,394.01 | 2019-2025 | Ruconest, Joenja |
| Astrazeneca Pharmaceuticals LP | $3,612.13 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,322.03 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $1,987.13 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $1,146.07 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,052.97 | 2020-2025 | Hyqvia, Takhzyro, Eohilia |
| Pfizer INC. | $879.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $848.14 | 2019-2025 | |
| Genzyme Corporation | $729.36 | 2019-2025 | |
| Amgen INC. | $614.00 | 2021-2025 | Tezspire |
| Shire North American Group INC | $270.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $208.78 | 2020-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $185.08 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.30 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $153.41 | 2021-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $149.49 | 2025 | Dawnzera |
| Mylan Specialty L.P. | $135.44 | 2019-2024 | Yupelri |
| Kaleo, INC. | $123.28 | 2019-2023 | Auvi-Q |
| Sunovion Pharmaceuticals INC. | $119.34 | 2019 | |
| Blueprint Medicines Corporation | $82.04 | 2023-2024 | Ayvakit |
| Grifols USA, LLC | $82.03 | 2020-2025 | Xembify |
| Nestle Healthcare Nutrition INC. | $67.96 | 2021-2022 | |
| Adma Biomanufacturing LLC | $63.94 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $60.39 | 2019-2023 | |
| Bio Products Laboratory USA, INC. | $58.66 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2022 | |
| Aimmune Therapeutics, INC. | $48.64 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $42.40 | 2024-2025 | Sajazir |
| Abbvie INC. | $34.08 | 2022 | |
| Octapharma USA, INC. | $30.57 | 2019 | |
| Galderma Laboratories, L.P. | $29.64 | 2025 | Nemluvio |
| Biocryst Pharmaceuticals, INC. | $16.53 | 2020 | |
| Leo Pharma INC. | $15.26 | 2024 | Adbry |
| Horizon Therapeutics Plc | $14.29 | 2022 | |
| Lilly USA, LLC | $14.24 | 2024 | Ebglyss |
| Phathom Pharmaceuticals, INC. | $5.26 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.